Enhancing Patient Outcomes in Metastatic Colorectal Cancer: Equipping Community, Veterans Affairs, and Oncology Pharmacists to Navigate Care in the Third-Line Setting and Beyond

In collaboration with COA.

Program Description

The majority of patients with metastatic colorectal cancer (mCRC) are characterized by microsatellite stable (MSS) or mismatch repair proficient (pMMR) tumors, which can be associated with limited responsiveness to immunotherapy and poorer long-term outcomes. Following progression on standard first- and second-line regimens, patients without actionable mutations enter a complex third-line (3L) treatment landscape. In these instances, evidence-based options such as regorafenib, trifluridine/tipiracil alone or with bevacizumab, and fruquintinib offer modest but meaningful survival benefits. These therapies, many of which are orally administered, introduce adherence challenges, nuanced dosing schedules, and toxicity management considerations that are often compounded by residual toxicities from prior therapies. Despite guideline recommendations supporting their use, real-world data suggest underutilization and retreatment with earlier lines, highlighting gaps in sequencing.

This webinar is designed for oncology pharmacists across community, Veterans Affairs, and ambulatory care settings and will provide practical guidance on therapy selection, pharmacogenomic considerations, and proactive toxicity management, including laboratory monitoring, early identification of adverse effects, and patient-specific counseling strategies for patients with mCRC. Emphasis will also be placed on emerging therapies and evolving evidence, interdisciplinary coordination, and the expanding role of pharmacist-led oral oncology services in optimizing adherence, safety, and outcomes in this increasingly complex later-line mCRC setting.

Target audience: Oncology pharmacists
Type of activity: Application
Release date: July 21, 2026
Expiration date: July 21, 2027
Learner level: Foundational
Time to complete activity: 1.25 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Apply current clinical evidence and molecular profiling to guide selection of third-line therapies in mismatch repair proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer (mCRC) without actionable mutations
• Identify common and serious adverse effects associated with third-line therapies for pMMR/MSS mCRC and their clinical presentation in patients
• Use effective patient counseling strategies to improve adherence, safe administration, and clinical benefit of third-line therapies in pMMR/MSS mCRC

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.25 contact hours (0.125 CEU) under the ACPE universal activity number 0290-0000-26-226-H01-P. The activity is available for CE credit through July 21, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Courtney C. Cavalieri, PharmD, BCOP, has the following relevant financial relationships with ineligible companies to disclose:

Consultant (advisory board): Bristol Myers Squibb, Daiichi Sankyo, Nuvalent

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Daphne Davis, PharmD, BCOP; Kylie Ferrentino; Brianna Winters; and Chloe Taccetta.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms